Merck & Co. Inc.

AI Score

XX

Unlock

93.68
-1.05 (-1.11%)
At close: Mar 21, 2025, 2:50 PM
-1.11%
Bid 93.67
Market Cap 236.64B
Revenue (ttm) 63.79B
Net Income (ttm) 17.02B
EPS (ttm) 6.74
PE Ratio (ttm) 13.9
Forward PE 10.49
Analyst Buy
Ask 93.69
Volume 9,120,511
Avg. Volume (20D) 14,225,698
Open 94.58
Previous Close 94.73
Day's Range 93.10 - 94.68
52-Week Range 81.04 - 134.63
Beta 0.36

About MRK

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops...

Sector Healthcare
IPO Date Jan 13, 1978
Employees 73,000
Stock Exchange NYSE
Ticker Symbol MRK
Full Company Profile

Analyst Forecast

According to 14 analyst ratings, the average rating for MRK stock is "Buy." The 12-month stock price forecast is $111, which is an increase of 18.49% from the latest price.

Stock Forecasts

Next Earnings Release

Merck & Co. Inc. is scheduled to release its earnings on Apr 24, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago
-9.07%
Merck shares are trading lower after the company i... Unlock content with Pro Subscription
1 month ago
+2.5%
Merck shares are trading higher after the company announced WELIREG has gained FDA priority review.